KV Pharmaceutical Wins Approval for Generic Anti-Hypertension Drug
Posted on: Friday, 16 May 2008, 06:00 CDT
KV Pharmaceutical Company has received final approval from the FDA of its abbreviated new drug application to market its 50mg strength of metoprolol succinate extended-release tablets.
The company expects to begin shipping immediately. This product is a generic version of AstraZeneca's branded product, Toprol-XL. Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension used alone or in combination with other antihypertensive agents, for the long-term treatment of angina pectoris and for the treatment of stable, symptomatic heart failure of ischemic, hypertensive, or cardiomyopathic origin.
As a result of the 50mg approval, KV is now offering the complete line of all four dosage strengths of metoprolol succinate extended-release tablets, 200mg, 100mg, 50mg and 25mg. Based on the company's first-to-file status on its abbreviated new drug application for these two strengths, KV was accorded the benefit of a 180-day generic exclusivity period for the marketing of these two dosage strengths.
Source: Datamonitor
Related Articles
- Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
- New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
- FDA Approves CONCERTA(R) (Methylphenidate HCI) Extended-Release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
- Dey L.P. And Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
- Critical Therapeutics and Dey Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets
- FDA Approves ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for Critical Therapeutics, DEY Marketing Partner for Chronic Treatment of Asthma
- FDA Approves Astrazeneca's Once-Daily Seroquel XR(TM) Extended-Release Tablets for the Treatment of Schizophrenia
- IMPAX Signs Exclusive Supply and Distribution Agreement With DAVA Pharmaceuticals for Oxycodone Hydrochloride Extended Release Tablets
- ALLEGRA-D(R) 24 Hour (Fexofenadine HCl 180 Mg/Pseudoephedrine HCl 240 Mg) Extended Release Tablets Now Available for Seasonal Allergy Sufferers
- New Study Reports Treatment With TOPROL-XL(R) (Metoprolol Succinate) Extended-Release Tablets for Hypertensive Children
 |
 |
User Comments (0)
RSS Feeds